Chest
Original Research: Chest InfectionsLung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease
Section snippets
Study Population
Using the database of the prospective NTM Registry cohort of Samsung Medical Center (a 1,979-bed referral hospital in Seoul, South Korea), we identified 438 consecutive patients in whom NTM-LD was diagnosed between January 1999 and November 2011 and who underwent spirometry at the time of diagnosis of NTM-LD and again at least 3 years later. Fifty-three patients who underwent surgical resection for NTM-LD during the follow-up period, 22 patients who had other chronic LDs (interstitial LD,
Baseline Characteristics
Of 358 patients, there were 118 in the observation group, 172 in the treatment-success group, and 68 in the treatment-failure group (including 10 patients who discontinued antibiotic treatment within 12 months) (Table 1). Female patients were more common in the treatment-success group (73.3%) than in the observation and treatment-failure groups (56.8% and 50.0%, respectively; P = .001). Patients in the observation group were more likely to have higher body mass index (median, 21.4 kg/m2
Discussion
To our knowledge, this is the largest longitudinal study to evaluate the impact of NTM-LD on the change of lung function based on treatment status and treatment outcomes. We evaluated 358 patients over a median follow-up period of 5.6 years to access the impact of treatment on lung function decline seen on spirometry. We found that treatment failure in patients with NTM-LD was associated with greater declines in FEV1 and FVC than was seen in the group undergoing observation only or in the
Acknowledgments
Author contributions: H. Y. P., B-H. J., and W-J. K. were responsible for the conception and design. H. Y. P. and B-H. J. were responsible for data analysis. H. Y. P., B-H. J., H. R. C., and W-J. K. were responsible for data interpretation and writing the manuscript. H. Y. P., B-H. J., H. R. C., K. J., C. L. D., and W-J. K. were responsible for revision of the manuscript and contribution to intellectual content.
Financial/nonfinancial disclosures: The authors have reported to CHEST the
References (47)
- et al.
Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review
Clin Chest Med
(2015) - et al.
Update on pulmonary disease due to non-tuberculous mycobacteria
Int J Infect Dis
(2016) - et al.
Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease
Chest
(2012) - et al.
Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease
Chest
(2014) - et al.
A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease
Respir Med
(2014) - et al.
Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease
Respir Med
(2011) - et al.
Update on the epidemiology of pulmonary nontuberculous mycobacterial infections
Semin Respir Crit Care Med
(2013) - et al.
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study
Eur Respir J
(2013) - et al.
Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea
Tuberc Respir Dis (Seoul)
(2013) - et al.
Distribution of nontuberculous mycobacteria by multigene sequence-based typing and clinical significance of isolated strains
J Clin Microbiol
(2014)
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
Am J Respir Crit Care Med
When and how to treat pulmonary non-tuberculous mycobacterial diseases
Respirology
Pulmonary non-tuberculous mycobacterial infections
Int J Tuberc Lung Dis
Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives
Tuberc Respir Dis (Seoul)
Antibiotic treatment for nontuberculous mycobacterial lung disease
Expert Rev Respir Med
Diagnosis and treatment of nontuberculous mycobacterial lung disease
J Korean Med Sci
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease
Am J Respir Crit Care Med
Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease
Am J Respir Crit Care Med
Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species
Am J Respir Crit Care Med
Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease
Antimicrob Agents Chemother
Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease
Int J Tuberc Lung Dis
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients
Am J Respir Crit Care Med
Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease
Clin Infect Dis
Cited by (0)
Drs Park and Jeong contributed equally to this work.
FUNDING/SUPPORT: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A2A1A01003959) and by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, South Korea (HI15C2778).